FDA approves six month implant for treatment of opioid dependence

Courtesy of Braeburn Pharmaceuticals The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the first long-acting, subdermal buprenorphine implant for the treatment of opioid...
Source: NIDA News - Category: Addiction Tags: Health and Medical Professionals, Opioids, Researchers, Treatment Research Source Type: news